Healthcare

Neuren Pharmaceuticals (ASX: NEU) returned to the spotlight in the latest session, with the ASX healthcare stock changing hands at about A$16.088, a gain of roughly 6.08% or close to A$0.79 a share. For a company that sits within the more specialised end of …

Mesoblast Limited (ASX: MSB) has reasserted itself as one of the more talked-about names on the Australian stock market, with the regenerative medicine developer leading the gainers board during a busy session. The MSB share price was last seen near A$2.08, representing a move …

dorsaVi Limited (ASX:DVL) shares advanced 2.50% to AUD 0.041 during the morning session on 18 June 2026 after the company announced that it had finalised the design package for its first integrated RRAM-CMOS validation chip. The stock remains up 105.00% over the past year, …

Regulatory designations of this kind are not, on their own, a guarantee of commercial success. They are, however, meaningful signposts. For a company whose progress to date has been measured largely by scientific rationale and pre-clinical or early-stage work, an engagement with a regulator …

Cardiac ablation is a well-established treatment approach for certain heart-rhythm disorders, in which targeted energy is used to address the tissue responsible for abnormal electrical activity. The novelty in Imricor's approach lies not in the concept of ablation itself, but in performing it within …

On its surface, a supply agreement may sound like an administrative footnote rather than a headline event. In the context of small-cap biotech, however, the reliable sourcing of clinical-grade drug product is anything but trivial. Manufacturing bottlenecks, supply interruptions and quality issues are among …

Neurizon Therapeutics Limited (ASX:NUZ) traded at A$0.065 on 17 June 2026, recording a 3.17% intraday gain following the announcement of a strategic long-term supply agreement with Elanco Animal Health.